JKT · KLBF.JK
PT Kalbe Farma Tbk.
IDR 735+IDR 20 (+2.8%)
PT Kalbe Farma Tbk.’s quoted price sits in the lower half of its reported 52-week range, 45.15% below the high.
Loading market information…
OTC · MYCOF · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Noveris Health Sciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.22% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Noveris Health Sciences Inc.’s next earnings report is currently expected on Nov 17, 2026, with estimated earnings per share of -$40.38. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Noveris Health Sciences Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Noveris Health Sciences Inc. operates as a biotechnology firm dedicated to the investigation, pharmaceutical development, and clinical evaluation of psilocybin-based products. Co-founded by Parente Carman, Damon Michaels, and Robert Roscow on September 27, 2013, the company maintains its headquarters in Vancouver, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2024 | Aug 19, 2024 | -$0.03 | $0.00 |
|---|
| Q1 2024 | Jun 4, 2024 | -$0.01 | $0.00 |
|---|
| Q3 2023 | Nov 15, 2023 | -$0.30 | $0.00 |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
IDR 735+IDR 20 (+2.8%)
PT Kalbe Farma Tbk.’s quoted price sits in the lower half of its reported 52-week range, 45.15% below the high.
CA$0.31+CA$0.02 (+5.08%)
Telescope Innovations Corp.’s quoted price sits in the lower half of its reported 52-week range, 71.82% below the high.
$0.25$0.00 (0.0%)
BioQuest Corp.’s quoted price sits in the lower half of its reported 52-week range, 75.0% below the high.
$0.03$0.00 (0.0%)
Quest PharmaTech Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.23% below the high.
SEK 7.61+SEK 0.01 (+0.13%)
Vivesto AB’s quoted price sits in the lower half of its reported 52-week range, 72.12% below the high.
$0.05$0.00 (0.0%)
Gemina Laboratories Ltd.’s quoted price sits in the lower half of its reported 52-week range, 85.46% below the high.
$0.02$0.00 (0.0%)
Herbal Dispatch Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.17% below the high.
$0.06+$0.00 (+5.45%)
Biotricity, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.17% below the high.
